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Background: Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat®
SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function
in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and
long-acting β2-agonists. To further explore the dose–response curve in asthma, we investigated the efficacy and safety of
three different doses of tiotropium Respimat® as add-on to ICS in symptomatic patients with moderate persistent asthma.
Methods: In this randomised, double-blind, placebo-controlled, four-way crossover study, patients were randomised to
tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg or placebo Respimat®, once daily in the evening. Each treatment
was administered for 4 weeks, without washout between treatment periods. Eligibility criteria included ≥60%
and ≤90% of predicted normal forced expiratory volume in 1 second (FEV1) and seven-question Asthma Control
Questionnaire mean score of ≥1.5. Patients were required to continue maintenance treatment with stable
medium-dose ICS for at least 4 weeks prior to and during the treatment period. Long-acting β2-agonists were
not permitted during the treatment phase. The primary efficacy end point was peak FEV1 measured within 3 hours after
dosing (peak FEV1(0-3h)) at the end of each 4-week period, analysed as a response (change from study baseline).
Results: In total, 149 patients were randomised and 141 completed the study. Statistically significant improvements in
peak FEV1(0-3h) response were observed with each tiotropium Respimat® dose versus placebo (all P < 0.0001). The
largest difference from placebo was with tiotropium Respimat® 5 μg (188 mL). Trough FEV1 and FEV1 area under the
curve (AUC)(0-3h) responses were greater with each tiotropium Respimat® dose than with placebo (all P < 0.0001), and
both were greatest with 5 μg. Peak forced vital capacity (FVC)(0-3h), trough FVC and FVC AUC(0-3h) responses, versus
placebo, were greatest with tiotropium Respimat® 5 μg (P < 0.0001, P = 0.0012 and P < 0.0001, respectively). Incidence
of adverse events was comparable between placebo and all tiotropium Respimat® groups.
Conclusions: Once-daily tiotropium Respimat® add-on to medium-dose ICS improves lung function in symptomatic
patients with moderate asthma. Overall, improvements were largest with tiotropium Respimat® 5 μg.
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Currently, inhaled corticosteroids (ICS) are the de facto
first-line therapy for the management of poorly controlled,
persistent asthma. In accordance with the Global Initiative
for Asthma guidelines [1], for patients with moderate
asthma who remain symptomatic despite using ICS, ther-
apy is typically ‘stepped up’ by increasing the ICS dose
and/or adding a long-acting β2-agonist (LABA) to the
maintenance treatment regimen. Leukotriene modifiers or
sustained-release theophylline, added on to low-dose ICS,
are alternative options for these patients. Despite this
range of therapeutic choices, at least 40% of patients with
asthma have poorly controlled disease [2-4]. Further, in
patients who fail to gain control with an ICS + LABA
fixed-dose combination, the remaining options, such as
further upwards titration of ICS, systemic glucocorti-
costeroids and anti-immunoglobulin E therapy, may have
several limitations with respect to side effects, risk:benefit
ratio, convenience and efficacy [1,5,6].
Tiotropium, a once-daily long-acting anticholinergic
bronchodilator, is the established first-line maintenance
bronchodilator for the management of chronic obstructive
pulmonary disease [7,8]. Recently, a number of clinical tri-
als have investigated tiotropium as add-on to at least ICS
for the long-term control of asthma, across a range of
severities. In the investigator-led TALC trial (Tiotropium
Bromide as an Alternative to Increased Inhaled Gluco-
corticoid in Patients Inadequately Controlled on a Lower
Dose of Inhaled Corticosteroid; three-way crossover,
14 weeks per treatment, 210 patients), improvements in
lung function in patients with asthma treated with tiotro-
pium (via HandiHaler®; Boehringer Ingelheim Pharma
GmbH & Co. KG, Ingelheim am Rhein, Germany) plus
beclomethasone (two puffs of 40 μg, twice daily) were
shown to be superior to a doubling of the ICS dose and
similar to the addition of salmeterol [9]. In a 16-week
proof-of-concept trial in B16-Arg/Arg patients with symp-
tomatic moderate asthma already receiving ICS, tiotro-
pium 5 μg (administered via the Respimat® SoftMist™
inhaler [hereinafter referred to as tiotropium Respimat®;
Boehringer Ingelheim Pharma GmbH & Co. KG]) was su-
perior to placebo Respimat® and non-inferior to salmeterol
[10]. A second proof-of-concept study (three-way cross-
over, 8 weeks per treatment) in patients with more severe
disease – severe persistent asthma, and receiving ICS +
LABA – demonstrated that lung function improved sig-
nificantly with tiotropium Respimat® 10 μg or 5 μg [11].
Slightly higher peak forced expiratory volume in 1 second
(FEV1) responses were observed in the 10 μg arm [11],
and there were statistically significant improvements in
pre-dose morning and evening peak expiratory flow
(PEFam and PEFpm) with 10 μg versus 5 μg. Kerstjens and
colleagues subsequently reported results from two long-
term, replicate, 1-year Phase III trials of tiotropiumRespimat® 5 μg, also in patients with symptomatic severe
asthma despite using ICS + LABA. In this cohort of 912
patients, tiotropium Respimat® 5 μg, administered as
add-on to ICS + LABA, significantly reduced the risk
of severe exacerbations and improved lung function,
compared with placebo Respimat® as add-on to ICS +
LABA [12].
In light of the findings with the 10 μg and 5 μg doses
of tiotropium Respimat® (outlined above), the aim of the
present study was to further explore the dose–response
curve by comparing the efficacy and tolerability of once-
daily evening dosing of tiotropium Respimat® 5 μg,
2.5 μg or 1.25 μg, versus placebo Respimat®, each added on
to medium-dose ICS, in adult patients with symptomatic
moderate asthma.
Methods
This was a Phase II, randomised, double-blind, placebo-
controlled, crossover study to investigate the efficacy and
safety of three doses of once-daily tiotropium Respimat®.
The study was conducted in 19 sites in three European
countries (Germany, Austria and Ukraine; ClinicalTrials.
gov identifier NCT01233284), and was carried out in ac-
cordance with the principles of the Declaration of Helsinki
and the International Conference on Harmonisation Good
Clinical Practice Guidelines. All patients provided written,
informed consent.
Study design
After an initial screening visit and a 4-week run-in
period, patients were randomised to one of four treat-
ment sequences, during which they received each of the
four treatments (tiotropium 5 μg, 2.5 μg or 1.25 μg or
placebo, all delivered via the Respimat® SoftMist™ inhaler)
(Figure 1). Each treatment was administered for 4 weeks,
and there was no washout between treatment periods as
pharmacodynamic steady state with tiotropium is known
to be achieved after 3 weeks in chronic obstructive pul-
monary disease [13,14]. Seven clinic visits were scheduled:
at screening (Visit 0); prior to the 4-week run-in (Visit 1);
at randomisation (after the 4-week run-in [Visit 2]); every
4 weeks at the end of each treatment period (Visits 3–6);
and 21 days following the end of the final treatment
period (Visit 7).
Tiotropium Respimat® (two puffs) or placebo Respimat®
(two puffs) was administered once daily in the evening
between 18:00 and 20:00. All patients were required to
continue maintenance treatment with stable medium-
dose ICS (400–800 μg budesonide or equivalent) for at
least 4 weeks prior to Visit 1 and until Visit 7. Patients
using ICS plus short-acting β2-agonist or ICS + LABA
fixed-dose combinations were switched to the same dose
of ICS mono-product at least 8 or 24 hours, respectively,















Treatment period 1 Treatment period 2 Treatment period 3 Treatment period 4
Tiotropium Respimat® 5 µg Tiotropium Respimat® 1.25 µg Tiotropium Respimat® 2.5 µgPlacebo Respimat®Treatment sequence 1
Tiotropium Respimat® 2.5 µg Placebo Respimat® Tiotropium Respimat® 5 µgTiotropium Respimat® 1.25 µgTreatment sequence 2
Tiotropium Respimat® 1.25 µg Tiotropium Respimat® 2.5 µg Placebo Respimat®Tiotropium Respimat® 5 µgTreatment sequence 3
Placebo Respimat® Tiotropium Respimat® 5 µg Tiotropium Respimat® 1.25 µgTiotropium Respimat® 2.5 µgTreatment sequence 4
Visit
19
Figure 1 Study design.
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in the evening. Concomitant use of the following was not
permitted for maintenance treatment: systemic oral or
depot corticosteroids; anticholinergics other than tiotro-
pium; LABAs; ICS plus short-acting β2-agonist or ICS +
LABA fixed-dose combinations; leukotriene modifiers;
anti-immunoglobulin E treatment; chromone; methylxan-
thines; and phosphodiesterase-4 inhibitors. Salbutamol
hydrofluoroalkane metered-dose inhaler was provided
by the sponsor as rescue medication for use as needed.
Permitted medication for the treatment of acute asthma
exacerbations included salbutamol hydrofluoroalkane
metered-dose inhaler, systemic corticosteroids and short-
acting theophylline preparations.
Randomisation
Each patient received all treatments. Eligible patients
were randomly allocated to one of the four treatment
sequences at Visit 2 (Figure 1). The randomisation list
was generated by Boehringer Ingelheim Pharma GmbH &
Co. KG, Biberach an der Riss, Germany, using a validated
pseudo-random number generator and a supplied seed
number. A fixed block randomisation, with a block size of
4, was used to ensure balanced and equal assignment.
Study patients
Male or female patients aged 18–75 years, with at least a
3-month history of asthma at the time of enrolment and
an initial diagnosis of asthma made before the age of
40 years, were included in the study. Patients were required
to have been on maintenance treatment with stable
medium-dose ICS (400–800 μg budesonide or equivalent),
alone or in a fixed-dose combination with a LABA or
short-acting β2-agonist, for at least 4 weeks prior to Visit 1.
A diagnosis of asthma confirmed at Visit 1 was required,with bronchodilator reversibility (15–30 minutes after
400 μg salbutamol) of ≥12% and ≥200 mL. Patients were
required to have a seven-question Asthma Control Ques-
tionnaire (ACQ-7) mean score of ≥1.5 at Visits 1 and 2, to
have a pre-bronchodilator FEV1 of ≥60% and ≤90% of pre-
dicted normal FEV1 at Visit 1, and to demonstrate absolute
FEV1 variability within 30% between Visits 1 and 2. Pa-
tients were required never to have smoked, or to be ex-
smokers who had stopped smoking at least 1 year prior to
enrolment and had a smoking history of less than 10 pack-
years. Patients were excluded for any of the following rea-
sons: a diagnosis of chronic obstructive pulmonary disease
or any respiratory disease other than asthma; myocardial
infarction within the last 6 months; hospitalisation due to
cardiac failure or unstable cardiac arrhythmia within the
past year; treatment with anti-immunoglobulin E anti-
bodies within 6 months prior to Visit 1.
Study end points
All end points were determined at the end of each
4-week treatment period (Visits 3–6) and analysed as
a response defined as change from study baseline
(pre-treatment value measured at Visit 2 in the evening).
The primary efficacy end point was peak FEV1 measured
within the first 3 hours after dosing (peak FEV1(0-3h)). The
following secondary efficacy end points were investigated:
trough FEV1; peak forced vital capacity (FVC) within the
first 3 hours after dosing (FVC)(0-3h); trough FVC; FEV1
area under the curve (AUC) within the first 3 hours after
dosing (FEV1 AUC(0-3h)); FVC AUC(0-3h); pre-dose PEFam
and PEFpm using the Asthma Monitor2+ device (AM2+®;
ERT, Philadelphia, Pennsylvania, USA) based on the mean
of the final week of each treatment period. Control of
asthma, as assessed by ACQ-7 self-administered at the
end of each 4-week treatment period, was an additional
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based on the incidence and intensity of adverse events,
and on changes in vital signs.
Study assessments
Spirometric lung function tests were conducted at all
in-clinic visits (Visits 1–6). Pre-dose lung function tests
were scheduled between 18:00 and 20:00. At Visits 2–6,
lung function tests were performed 10 minutes prior to
and up to 3 hours after dosing of study treatment. ACQ-7
was self-administered at Visits 1–6 prior to lung function
tests. Measurement of PEFam and PEFpm was to be per-
formed prior to ICS and study treatment inhalation, atDiscontinued treatment
(n=3; 2.0%)
–  Consent withdrawn
    (n=2; 1.4%)
–  Other




    discontinuation
    due to adverse event
    (n=1; 0.7%)
–  Lost to follow-up
    (n=1; 0.7%)
–  Consent withdrawn

















Figure 2 Patient disposition.approximately the same time each day, from 06:00 to
08:00 for PEFam and from 18:00 to 20:00 for PEFpm. Ad-
verse events and concomitant medications were recorded
on the electronic case report form at each visit. Vital signs
were measured and recorded in conjunction with lung
function tests at Visits 2–6.
Statistical analyses
Efficacy data are reported for the full analysis set, which
was defined as all randomised patients who were treated
with at least one dose of study medication, had baseline
data and had at least one on-treatment efficacy measure-
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–  Other
























Body mass index, kg/m2 a 26.9 ± 4.3
Smoking status, n (%)
Current smoker 0
Ex-smoker 29 (19.5)
Never smoked 120 (80.5)
Smoking history, pack-yearsa 5.6 ± 2.5
Duration of asthma, yearsa 23.8 ± 13.4
FEV1
a
% of predicted value pre-bronchodilation
at screeningb
71.3 ± 7.1
% of predicted value post-bronchodilation
at screeningb
87.4 ± 10.2
Reversibility, Lb 0.500 ± 0.239
% reversibilityb 22.8 ± 10.2
Pre-dose at study baseline, Lc 2.306 ± 0.689
c a
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after 4 weeks of treatment (defined as response), unless
noted otherwise.
Evaluation of safety and tolerability was performed on
the treated set, defined as all randomised patients who
received at least one dose of study medication. Analysis of
adverse events and vital signs was descriptive in nature.
To control the probability of a type I error in the pri-
mary efficacy analysis, stepwise testing of the null hypoth-
esis was used to test the efficacy of tiotropium Respimat®
5 μg, then 2.5 μg and then 1.25 μg, each over placebo
Respimat®. If the previous step was not successful, analysis
of the current step was to be considered descriptive. To
detect a treatment difference of 80 mL for peak FEV1(0-3h)
with 90% power, and assuming a standard deviation
of 228 mL, it was calculated that 88 completed patients
were required. Testing was performed with α = 0.025
(one-sided).
The pre-specified hypotheses were tested using a
mixed effects model with repeated measures. The sta-
tistical model included ‘treatment’ and ‘period’ as fixed
effects and ‘patient’ as a random effect. Study baseline,
defined as pre-treatment values measured at Visit 2 in
the evening, was included as covariate.FVC, pre-dose at baseline , L 3.639 ± 0.978
FEV1/FVC ratio at baseline
c, %a 63.7 ± 10.1
ICS dose of stable maintenance treatment, μga,d 659.2 ± 249.4
aValues are mean ± standard deviation; bVisit 1; cMeasured 10 minutes prior to
inhalation of study medication at Visit 2 (at randomisation); dBudesonide
equipotent dose. FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; ICS, inhaled corticosteroids.Results
Baseline demographics and disposition
A total of 149 patients were randomised to the study,
and 141 patients completed the study. The treated set
comprised all 149 patients and the full analysis set com-
prised 148 patients (one patient had missing efficacy
data and was lost to follow-up after Visit 2) (Figure 2).
In the treated set, slightly more patients were female
(55.0%) than male (45.0%), mean age was 49.3 years and
mean body mass index was 26.9 kg/m2 (Table 1). Of the
small proportion of patients who had previously smoked
(19.5%; n = 29), the mean number of pack-years was 5.6.
The remainder of the study population had never smoked
(80.5%; n = 120) (Table 1).Efficacy
Primary analysis
The addition of tiotropium Respimat® 5 μg, 2.5 μg or
1.25 μg to stable medium-dose ICS therapy was asso-
ciated with improved lung function: at the end of the
4-week treatment period, statistically significant differ-
ences from placebo Respimat® in adjusted mean peak
FEV1(0-3h) responses were observed for all doses of
tiotropium Respimat® (P < 0.0001 at all doses) (Figure 3).
The largest adjusted mean difference from placebo Res-
pimat® was observed with tiotropium Respimat® 5 μg
(188 mL, 95% confidence interval: 140, 236).Secondary analyses
Trough FEV1, FEV1 AUC(0-3h), peak FVC(0-3h), trough
FVC and FVC AUC(0-3h) responses with all doses of
tiotropium Respimat® were larger than the responses ob-
served with placebo Respimat®, and all were statistically
significant except for trough FVC in the 1.25 μg group
(Figure 3, Additional file 1: Table S1). Responses for each
of these end points were all largest in the 5 μg group
(Figure 3, Additional file 1: Table S1).
Exploratory analysis of the difference in response
between tiotropium Respimat® doses found that peak
FEV1(0-3h), FEV1 AUC(0-3h), peak FVC(0-3h) and FVC
AUC(0-3h) responses were all statistically significantly
greater with tiotropium Respimat® 5 μg than with either of
the two lower doses (Table 2).
At the end of each 4-week treatment period, there was
a statistically significant improvement in ACQ-7 score
with all three tiotropium Respimat® doses (Additional
file 1: Table S1).
Higher mean pre-dose PEFam responses (measured
with the AM2+® device) were observed with all three tio-














































































































































































Figure 3 Adjusted mean differences in lung function responses. (A) Peak FEV1(0-3h) response; (B) Trough FEV1 response; (C) Peak FVC(0-3h)
response; (D) Trough FVC response. Response defined as change from study baseline (pre-treatment value measured at Visit 2 in the evening).
Adjusted mean difference from placebo Respimat®: *P < 0.001; **P < 0.01; ***P < 0.05. Bars: standard error. FEV1, forced expiratory volume in
1 second; FVC, forced vital capacity; NS, not significant; peak FEV1(0-3h), peak forced expiratory volume in 1 second measured within the first
3 hours after dosing; peak FVC(0-3h), peak forced vital capacity measured within the first 3 hours after dosing.
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2.5 μg, 17.895 L/min; 1.25 μg, 18.550 L/min; all P < 0.0001).
Higher mean pre-dose PEFpm responses were also observed
with all three tiotropium Respimat® treatments compared
with placebo Respimat® (difference from placebo: 5 μg,
21.581 L/min; 2.5 μg, 14.577 L/min; 1.25 μg, 21.251 L/min;
all P < 0.0001). No significant differences in PEFam or PEFpm
responses were observed between the different tiotropium
Respimat® doses.
Safety and tolerability
Overall incidence of adverse events was comparable
between placebo Respimat® and the three tiotropium
Respimat® treatment doses (Table 3). Serious adverse
events were reported for two patients (in the tiotropium
Respimat® 5 μg group). Neither was considered to bedrug-related. One patient was reported with alcohol abuse
and panic attack, which led to hospitalisation. Both of this
patient’s adverse events accounted for discontinuation of
the study drug (the only case of discontinuation during
the trial). The other patient was reported with inguinal
hernia, which led to hospitalisation.
The most commonly reported adverse events by pre-
ferred term were asthma exacerbation and nasopharyngi-
tis. In the tiotropium Respimat® 5 μg group, one patient
reported dry mouth. No clinically relevant change in mean
vital sign values was associated with tiotropium Respimat®.
Discussion
In this dose-ranging study, tiotropium Respimat® was
found to be an effective once-daily bronchodilator as add-
on maintenance therapy in patients with symptomatic
Table 2 Adjusted mean differences in lung function responses between tiotropium Respimat® doses
Response parameter Adjusted mean differences between treatments (95% CI), mL
Tiotropium Respimat® 5 μg versus
tiotropium Respimat® 1.25 μg
Tiotropium Respimat® 5 μg versus
tiotropium Respimat® 2.5 μg
Tiotropium Respimat® 2.5 μg versus
tiotropium Respimat® 1.25 μg
FEV1
Peak FEV1(0-3h) 50 (2, 98) 60 (12, 108) −10 (−58, 38)
Trough FEV1 18 (−30, 66) 11 (−36, 59) 7 (−41, 54)
FEV1 AUC(0-3h) 49 (3, 95) 51 (5, 97) −2 (−48, 44)
FVC
Peak FVC(0-3h) 58 (5, 111) 67 (14, 120) −9 (−61, 44)
Trough FVC 44 (−15, 103) 27 (−33, 86) 17 (−42, 77)
FVC AUC(0-3h) 74 (22, 0.125) 63 (11, 114) 11 (−40, 62)
AUC, area under the curve; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FEV1 AUC(0-3h), forced expiratory volume in 1 second area under
the curve measured within the first 3 hours after dosing; FVC, forced vital capacity; FVC AUC(0-3h), forced vital capacity area under the curve measured within the
first 3 hours after dosing; peak FEV1(0-3h), peak forced expiratory volume in 1 second measured within the first 3 hours after dosing; peak FVC(0-3h), peak forced
vital capacity measured within the first 3 hours after dosing.
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doses of tiotropium Respimat® 5 μg, 2.5 μg or 1.25 μg,
administered for 4 weeks per treatment, were each associ-
ated with statistically significant improvements in lung
function compared with placebo Respimat®. Serious ad-
verse events were rare and considered unrelated to treat-
ment, and overall adverse-event incidence was comparable
between all treatment groups.
All three doses of tiotropium Respimat® produced
statistically significant improvements in the primary end
point (peak FEV1(0-3h) response) compared with placeboTable 3 Summary of adverse events in the treated set
n (%) Tiotropium Re
5 μga
(n = 146
Patients with any adverse event 23 (15.8
Patients with severe adverse events 2 (1.4)
Patients with serious adverse eventsb 2 (1.4)
Patients with investigator-defined drug-related adverse
events
3 (2.1)
Patients with adverse events leading to discontinuation
of study medication
1 (0.7)
Most frequently reported adverse events (>1 patient on any treatment






Respiratory, thoracic and mediastinal disorders 5 (3.4)
Asthma exacerbation 4 (2.7)
Dyspnoea 0
Cough 0
aAll patients in all groups on a background of maintenance treatment with stable m
bBoth patients experiencing serious adverse events required hospitalisation.Respimat®. However, the response to 5 μg was larger
than the responses to 2.5 μg and 1.25 μg, both of
which were similar in magnitude. Further, in all other
lung function parameters that were assessed, responses
were consistently largest with tiotropium Respimat® 5 μg.
Peak FEV1(0-3h), FEV1 AUC(0-3h), peak FVC(0-3h) and FVC
AUC(0-3h) responses were statistically significantly
greater with tiotropium Respimat® 5 μg versus either
of the lower doses. The adverse-event profile for 5 μg







) (n = 147) (n = 146) (n = 144)
) 20 (13.6) 14 (9.6) 21 (14.6)
0 0 0
0 0 0
0 2 (1.4) 2 (1.4)
0 0 0
per treatment period)
4 (2.7) 6 (4.1) 7 (4.9)
1 (0.7) 2 (1.4) 2 (1.4)
0 0 0
0 1 (0.7) 2 (1.4)
0 1 (0.7) 0
0 1 (0.7) 1 (0.7)
8 (5.4) 4 (2.7) 7 (4.9)
3 (2.0) 1 (0.7) 5 (3.5)
3 (2.0) 0 1 (0.7)
1 (0.7) 2 (1.4) 0
edium-dose inhaled corticosteroids (400–800 μg budesonide or equivalent);
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significant reduction in ACQ-7 scores at the end of each
4-week treatment period with each of the three tiotro-
pium Respimat® doses. However, the crossover design
and the relatively short, 4-week, treatment periods are
limitations with respect to drawing conclusions from the
ACQ-7 score analysis.
The lung function and tolerability findings of the
present trial are in accordance with those from previ-
ously published studies of tiotropium Respimat® as add-
on to ICS ± LABA in patients with symptomatic asthma
[10-12]. We await the results of two larger, replicate,
Phase III, 24-week, randomised, double-blind trials in
patients receiving moderate-dose ICS (NCT01172808
and NCT01172821).
Conclusions
We have reported the first investigation of three dif-
ferent doses of tiotropium Respimat® (5 μg, 2.5 μg or
1.25 μg) in a patient population with symptomatic
asthma treated with medium-dose ICS maintenance
therapy. Tiotropium Respimat® 5 μg was found to be
the most effective and consistent dose, with a safety
profile comparable with that of placebo, thereby pro-
viding support for further investigation of tiotropium
Respimat® in larger and longer-term Phase III trials in
this population.
Additional file
Additional file 1: Table S1. Adjusted mean differences in lung function
and ACQ-7 score between tiotropium Respimat® and placebo Respimat®.
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ACQ-7: Seven-question Asthma Control Questionnaire; AM2+®: Asthma
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